Psychedelic Therapies in the Management of Post-Traumatic Stress Disorder
Journal of Education Health and Sport July 16, 2026 Jakub Bajer, Aleksandra Włodarczyk, Hubert Kulawinek et al.
Psychedelic therapies, especially MDMA-assisted therapy, show promise for treating PTSD by targeting underlying causes rather than just symptoms. A review of studies found that MDMA-assisted therapy led to 67% of participants no longer meeting PTSD criteria at the study endpoint. Psilocybin effectively treats common comorbidities like anxiety and treatment-resistant depression, while ketamine offers rapid symptom relief for treatment-resistant cases with high risk of self-harm. These treatments work by inducing neuroplasticity and augmenting fear extinction through specific biological pathways. Despite regulatory challenges, standardized protocols are needed to ensure safety and reproducibility in future research.